Medical/dental insurance databases and drug safety surveillance

March 10, 2006

Recent failures of the Drug Safety Surveillance system in the United States and abroad, as evidenced by market withdrawals of commonly used medications, call attention to the many limitations to the monitoring of long-term drug safety. Although drug safety evaluation is primarily performed during clinical development, clinical trials are not efficient in identifying rare adverse effects. Similarly, the post-market system suffers from inherent limitations, including the under-reporting of voluntary reports of adverse effects.

As a source of healthcare utilization data, administrative insurance databases present a viable and efficient alternative for pro-active safety surveillance. Several serious adverse effects have now been identified from the analysis of medical claims, and successful surveillance programs have been put in place in the medical field.

Today, in a symposium being held as part of the 35th Annual Meeting of the American Association for Dental Research, scientists and speakers from the National Association of Dental Plans, Columbia University, Ingenix-United Health Care, and Harvard University will discuss dental plans in the US today, working with dental claims data, and medical claims-based drug safety surveillance, and a case study in bisphosphonates (a family of drugs used to prevent and treat osteoporosis) and osteonecrosis (a condition where part of the bone is no longer alive and cannot regenerate itself due to a lack of blood supply) will be presented.
This is a summary of a symposium, Sequence #117, entitled "Medical/Dental Insurance Databases and Drug Safety Surveillance", being presented at 10:45 a.m. on Friday, March 20, 2006, in Asia 3 of the Walt Disney World Dolphin Hotel, during the 35th Annual Meeting of the American Association for Dental Research.

International & American Associations for Dental Research

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to